诊断检测可遏制抗菌药物耐药威胁:感染病专业人员可发挥作用
该文指出提高现有诊断检测的使用率可更准确识别感染,减少不必要的抗生素使用并减缓耐药威胁。IDSA与PACCARB一致认为需更好的临床与经济结局数据、更好的工具与教育及联邦资助来促进诊断检测 uptake。文章总结诊断研发与应用的激励与挑战,并提供感染病专业人员参与抗耐药行动的倡导机会。
要点
- 提高现有诊断检测使用率可减少不必要抗生素使用并减缓耐药。
- 需更好的临床与经济结局数据支持诊断检测优于经验性抗生素。
- 感染病专业人员应参与倡导以推动诊断检测研发与应用。
核心结论
- 提高现有诊断检测的使用率可更准确识别感染,从而减少不必要抗生素使用并减缓耐药威胁。
主要发现
- IDSA与PACCARB一致认为需更好的临床与经济结局数据以支持诊断检测优于经验性抗生素使用。
- 提供者需要更好的诊断检测工具与教育,诊断开发者需要联邦资助以弥补可行诊断市场的缺失。
临床怎么用
- 感染病专业人员可参考文中倡导机会,参与推动诊断检测研发与应用的行动。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Uptake of existing diagnostics to identify infections more accurately could minimize unnecessary antibiotic use and decrease the growing threat of antibiotic resistance. The Infectious Diseases Society of America (IDSA) and the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) agree that, to improve uptake of existing diagnostics, healthcare providers, health systems, and payors all need better clinical and economic outcomes data to support use of diagnostic tests over empiric use of antibiotics, providers need better tools and education about diagnostic tests, and diagnostics developers need federal funding in the absence of a viable diagnostics market. Recommendations from PACCARB and the IDSA are amplified. Incentives for-and challenges to-diagnostics research, development, and uptake are summarized. Advocacy opportunities are given for infectious disease professionals to join the fight against antimicrobial resistance.
引用
- Trevas D, Caliendo AM, Hanson K, et al. Diagnostic Tests Can Stem the Threat of Antimicrobial Resistance: Infectious Disease Professionals Can Help. Clin Infect Dis. 2021. PMID: 33206946. doi:10.1093/cid/ciaa1527
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。